Related Experiment Video
Updated: May 12, 2026

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
Published on: May 16, 2016
Massive idiopathic pericardial effusion in a pediatric patient responsive to interleukin-1 receptor antagonist:
Mattia Pasquinucci1,2, Carmelo Marco Arcidiacono3, Stefano Volpi4
1Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, IRCCS Giannina Gaslini Institute, Genoa, Italy.
Insights
A child with chronic idiopathic pericardial effusion (PE) unresponsive to standard treatments was successfully managed with anakinra, an IL-1 receptor antagonist, highlighting biologic therapy for refractory pediatric PE.
Area of Science:
- Pediatric Cardiology
- Immunology
- Inflammatory Diseases
Background:
- Idiopathic pericardial effusion (PE) can be a chronic condition in children.
- Standard treatments like NSAIDs, corticosteroids, and colchicine are often ineffective for refractory cases.
- Identifying underlying inflammatory mechanisms is crucial for targeted therapy.
Abstract:
We report a child with massive, chronic idiopathic pericardial effusion (PE), initially detected incidentally and asymptomatically. Despite multiple treatment attempts, including Nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and repeated pericardiocentesis, the effusion persisted and recurred. Advanced imaging revealed a stable but severe PE over the years, with no hemodynamic compromise. Cytokine analysis of the pericardial fluid showed markedly elevated interleukin (IL)-6 levels, suggesting an underlying inflammatory process despite the absence of classic clinical signs. Based on this finding, the patient was successfully treated with anakinra, an IL-1 receptor antagonist, resulting in sustained remission for 24 months. This case highlights the potential role of biologic therapy in selected pediatric patients with chronic idiopathic PE, even when traditional markers of inflammation are absent. Cytokine profiling may help identify candidates for anti-IL-1 treatment, providing a valuable therapeutic option where standard approaches fail.
Related Concept Videos
Pericarditis I: Introduction
Pericarditis II: Clinical Features and Diagnostic Tests
Chronic Inflammation: Introduction
Pericarditis III: Medical Management
Myocarditis I: Introduction
Acute Inflammation II: Local and Systemic Effects
